Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

Denali Therapeutics remains an intriguing clinical-stage biotech focused on neurodegenerative and lysosomal storage diseases.

NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027 SOUTH SAN FRANCISCO ...

About LRRK2’s Role in Parkinson’s Disease and NEU-411. Mutations in the LRRK2 gene are among the most common genetic causes of PD, affecting approximately 2% of people with the disease.

"The Series D financing represents further endorsement of Neuron23’s industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU-411 to ...

US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on ...

Brenig's main focus at the moment is a preclinical-stage LRRK2 inhibitor, codenamed BT-267, that it intends to move into human safety trials and proof-of-concept studies in both LRRK2-mutated and ...

They may include agents to modulators of kinase activities (e.g., PINK1 and LRRK2), modulators of the activity of the ubiquitin–protein ligase, Parkin, proteostasis agents to block α-synuclein ...

About LRRK2’s Role in Parkinson’s Disease and NEU-411. Mutations in the LRRK2 gene are among the most common genetic causes of PD, affecting approximately 2% of people with the disease. Individuals ...